Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Tuberculosis | 14 | 2019 | 2895 | 1.79 | Why? |
| Mycobacterium tuberculosis | 9 | 2019 | 1164 | 1.78 | Why? |
| Tuberculosis, Multidrug-Resistant | 9 | 2019 | 433 | 1.74 | Why? |
| Antitubercular Agents | 12 | 2019 | 775 | 1.55 | Why? |
| Models, Theoretical | 12 | 2021 | 6659 | 1.51 | Why? |
| Latent Tuberculosis | 6 | 2019 | 324 | 0.95 | Why? |
| Rifampin | 4 | 2019 | 276 | 0.89 | Why? |
| Tuberculosis, Pulmonary | 4 | 2019 | 1171 | 0.80 | Why? |
| Basic Reproduction Number | 3 | 2020 | 2676 | 0.76 | Why? |
| Diarylquinolines | 1 | 2018 | 90 | 0.71 | Why? |
| Vancomycin-Resistant Enterococci | 1 | 2018 | 104 | 0.68 | Why? |
| Bayes Theorem | 6 | 2020 | 3237 | 0.61 | Why? |
| Virus Latency | 1 | 2017 | 251 | 0.58 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2018 | 323 | 0.56 | Why? |
| Models, Organizational | 1 | 2020 | 908 | 0.53 | Why? |
| Epidemics | 3 | 2020 | 6407 | 0.52 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.51 | Why? |
| Policy Making | 1 | 2020 | 829 | 0.50 | Why? |
| Communicable Diseases | 2 | 2018 | 2148 | 0.49 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.48 | Why? |
| Models, Statistical | 3 | 2021 | 5312 | 0.47 | Why? |
| Public Health Practice | 1 | 2020 | 945 | 0.46 | Why? |
| Drug Resistance, Bacterial | 2 | 2018 | 1414 | 0.43 | Why? |
| Health Policy | 3 | 2020 | 6242 | 0.43 | Why? |
| Isoniazid | 3 | 2019 | 105 | 0.39 | Why? |
| Ethiopia | 6 | 2019 | 1222 | 0.37 | Why? |
| Communicable Diseases, Emerging | 2 | 2020 | 2523 | 0.36 | Why? |
| Decision Making | 2 | 2020 | 3132 | 0.36 | Why? |
| Sentinel Surveillance | 3 | 2017 | 1093 | 0.36 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.34 | Why? |
| Australia | 9 | 2020 | 6306 | 0.33 | Why? |
| Retreatment | 2 | 2017 | 186 | 0.32 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.32 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.32 | Why? |
| Travel | 4 | 2021 | 7220 | 0.31 | Why? |
| Catheter-Related Infections | 1 | 2009 | 381 | 0.30 | Why? |
| Catheterization, Central Venous | 1 | 2009 | 458 | 0.28 | Why? |
| Communicable Disease Control | 4 | 2021 | 29620 | 0.25 | Why? |
| Markov Chains | 3 | 2019 | 502 | 0.24 | Why? |
| Public Health | 4 | 2020 | 16359 | 0.21 | Why? |
| Disease Outbreaks | 5 | 2020 | 27595 | 0.21 | Why? |
| Prothionamide | 1 | 2018 | 1 | 0.20 | Why? |
| Kanamycin | 1 | 2018 | 15 | 0.20 | Why? |
| Ofloxacin | 1 | 2018 | 23 | 0.20 | Why? |
| Sputum | 2 | 2018 | 1720 | 0.20 | Why? |
| Ethambutol | 1 | 2018 | 34 | 0.19 | Why? |
| Introduced Species | 1 | 2018 | 13 | 0.19 | Why? |
| Pneumonia, Viral | 9 | 2021 | 243684 | 0.19 | Why? |
| Pyrazinamide | 1 | 2018 | 38 | 0.19 | Why? |
| New South Wales | 1 | 2020 | 336 | 0.19 | Why? |
| Papua New Guinea | 4 | 2018 | 63 | 0.18 | Why? |
| Clofazimine | 1 | 2018 | 85 | 0.18 | Why? |
| Health Facilities | 2 | 2017 | 1230 | 0.18 | Why? |
| Bacteremia | 1 | 2009 | 1372 | 0.18 | Why? |
| Colony Count, Microbial | 1 | 2018 | 177 | 0.18 | Why? |
| Humans | 51 | 2021 | 930598 | 0.18 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.18 | Why? |
| Homosexuality, Male | 2 | 2017 | 1158 | 0.17 | Why? |
| Likelihood Functions | 1 | 2020 | 719 | 0.17 | Why? |
| Meteorological Concepts | 1 | 2019 | 345 | 0.17 | Why? |
| Antigens, Bacterial | 2 | 2018 | 330 | 0.17 | Why? |
| Drug Dosage Calculations | 1 | 2018 | 243 | 0.17 | Why? |
| Models, Economic | 1 | 2020 | 316 | 0.17 | Why? |
| Pandemics | 11 | 2021 | 389249 | 0.17 | Why? |
| Victoria | 3 | 2019 | 607 | 0.17 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.16 | Why? |
| Epidemiologic Methods | 1 | 2020 | 392 | 0.16 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.16 | Why? |
| Unsafe Sex | 1 | 2017 | 139 | 0.16 | Why? |
| Spatial Analysis | 2 | 2019 | 878 | 0.15 | Why? |
| Mycobacterium | 1 | 2017 | 143 | 0.15 | Why? |
| Rotavirus Vaccines | 1 | 2018 | 203 | 0.15 | Why? |
| Disease Eradication | 2 | 2020 | 581 | 0.14 | Why? |
| Rural Population | 2 | 2017 | 2408 | 0.14 | Why? |
| Rotavirus Infections | 1 | 2018 | 355 | 0.13 | Why? |
| Developing Countries | 2 | 2020 | 4283 | 0.13 | Why? |
| Incidence | 5 | 2019 | 25622 | 0.13 | Why? |
| Gastroenteritis | 1 | 2018 | 489 | 0.12 | Why? |
| Malaria, Falciparum | 1 | 2017 | 377 | 0.12 | Why? |
| Nigeria | 1 | 2020 | 2292 | 0.12 | Why? |
| Communicable Diseases, Imported | 1 | 2021 | 843 | 0.12 | Why? |
| Immunity, Herd | 1 | 2020 | 1011 | 0.12 | Why? |
| Population Density | 1 | 2017 | 694 | 0.12 | Why? |
| Spatio-Temporal Analysis | 1 | 2017 | 1182 | 0.11 | Why? |
| Chemokine CXCL10 | 1 | 2015 | 565 | 0.11 | Why? |
| Data Collection | 1 | 2020 | 1769 | 0.11 | Why? |
| User-Computer Interface | 1 | 2017 | 1068 | 0.10 | Why? |
| Autophagy | 1 | 2017 | 960 | 0.10 | Why? |
| Family Characteristics | 2 | 2020 | 2551 | 0.10 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.10 | Why? |
| Urban Population | 2 | 2017 | 2000 | 0.10 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.10 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.09 | Why? |
| HIV Infections | 4 | 2019 | 11620 | 0.09 | Why? |
| Tuberculin Test | 2 | 2019 | 141 | 0.09 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.09 | Why? |
| Infant | 7 | 2020 | 30274 | 0.09 | Why? |
| Netherlands | 1 | 2017 | 3533 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.09 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.08 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.08 | Why? |
| Cross Infection | 1 | 2009 | 8675 | 0.08 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.08 | Why? |
| Observer Variation | 1 | 2009 | 622 | 0.08 | Why? |
| Placenta | 1 | 2017 | 1531 | 0.08 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.08 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Medical Records | 1 | 2009 | 513 | 0.08 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.08 | Why? |
| Computer Simulation | 2 | 2018 | 4982 | 0.08 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.08 | Why? |
| Monte Carlo Method | 2 | 2019 | 577 | 0.07 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.07 | Why? |
| Child, Preschool | 6 | 2020 | 36283 | 0.07 | Why? |
| Diarrhea | 1 | 2017 | 2743 | 0.07 | Why? |
| Government Programs | 1 | 2009 | 512 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Adolescent | 10 | 2020 | 86841 | 0.07 | Why? |
| Intensive Care Units | 2 | 2017 | 29594 | 0.07 | Why? |
| Young Adult | 10 | 2020 | 93724 | 0.07 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.06 | Why? |
| Male | 19 | 2020 | 367725 | 0.06 | Why? |
| Disease Progression | 2 | 2019 | 13580 | 0.06 | Why? |
| Female | 18 | 2020 | 380317 | 0.06 | Why? |
| Gastrointestinal Diseases | 1 | 2017 | 2580 | 0.06 | Why? |
| Child | 7 | 2020 | 70012 | 0.06 | Why? |
| Adult | 15 | 2020 | 244371 | 0.06 | Why? |
| Demography | 2 | 2019 | 1660 | 0.05 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.05 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.05 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.05 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.05 | Why? |
| Culture Techniques | 1 | 2018 | 36 | 0.05 | Why? |
| Meteorology | 1 | 2019 | 114 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Temperature | 2 | 2019 | 2305 | 0.05 | Why? |
| Enteropathogenic Escherichia coli | 1 | 2017 | 11 | 0.05 | Why? |
| Enterotoxigenic Escherichia coli | 1 | 2017 | 15 | 0.05 | Why? |
| Phagosomes | 1 | 2017 | 32 | 0.04 | Why? |
| Asymptomatic Infections | 1 | 2017 | 7218 | 0.04 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.04 | Why? |
| Campylobacter | 1 | 2017 | 34 | 0.04 | Why? |
| Shigella | 1 | 2017 | 27 | 0.04 | Why? |
| Cold Temperature | 1 | 2019 | 260 | 0.04 | Why? |
| Antibiotics, Antitubercular | 1 | 2017 | 65 | 0.04 | Why? |
| Geography, Medical | 1 | 2020 | 537 | 0.04 | Why? |
| Self Administration | 1 | 2017 | 125 | 0.04 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.04 | Why? |
| Antisepsis | 1 | 2017 | 30 | 0.04 | Why? |
| Health Services Accessibility | 2 | 2019 | 10697 | 0.04 | Why? |
| Urbanization | 1 | 2017 | 133 | 0.04 | Why? |
| Risk | 2 | 2021 | 5288 | 0.04 | Why? |
| Interferon-gamma Release Tests | 1 | 2018 | 253 | 0.04 | Why? |
| Socioeconomic Factors | 3 | 2019 | 8495 | 0.04 | Why? |
| Aged | 8 | 2020 | 215776 | 0.04 | Why? |
| Mental Disorders | 1 | 2018 | 6742 | 0.04 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.04 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.04 | Why? |
| Stress, Psychological | 1 | 2018 | 10231 | 0.03 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2009 | 2984 | 0.03 | Why? |
| Lysosomes | 1 | 2017 | 416 | 0.03 | Why? |
| Helicobacter pylori | 1 | 2017 | 262 | 0.03 | Why? |
| Microscopy | 1 | 2017 | 414 | 0.03 | Why? |
| Logistic Models | 2 | 2019 | 9089 | 0.03 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Indonesia | 1 | 2018 | 1022 | 0.03 | Why? |
| Air Travel | 1 | 2021 | 585 | 0.03 | Why? |
| Sensitivity and Specificity | 2 | 2017 | 22971 | 0.03 | Why? |
| Norovirus | 1 | 2017 | 294 | 0.03 | Why? |
| Unemployment | 1 | 2020 | 702 | 0.03 | Why? |
| Weather | 1 | 2019 | 581 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.03 | Why? |
| Emigration and Immigration | 1 | 2017 | 501 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Regression Analysis | 1 | 2019 | 2484 | 0.03 | Why? |
| Cluster Analysis | 1 | 2019 | 3001 | 0.03 | Why? |
| New Zealand | 1 | 2017 | 2073 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Research Design | 2 | 2018 | 5830 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.03 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.02 | Why? |
| Contact Tracing | 2 | 2019 | 8448 | 0.02 | Why? |
| BCG Vaccine | 1 | 2019 | 1137 | 0.02 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Psychotic Disorders | 1 | 2018 | 924 | 0.02 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.02 | Why? |
| Neuraminidase | 1 | 2009 | 289 | 0.02 | Why? |
| Odds Ratio | 1 | 2019 | 5861 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2017 | 1019 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Seasons | 1 | 2019 | 4071 | 0.02 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Influenza, Human | 1 | 2009 | 10779 | 0.02 | Why? |
| Schools | 1 | 2020 | 4187 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.02 | Why? |
| Population Surveillance | 1 | 2021 | 4967 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Feces | 1 | 2017 | 4235 | 0.02 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.02 | Why? |
| Drug Resistance, Viral | 1 | 2009 | 1083 | 0.02 | Why? |
| Sex Factors | 1 | 2019 | 11014 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Hospitals | 1 | 2019 | 11793 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 8811 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Antiviral Agents | 1 | 2009 | 41703 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Depression | 1 | 2018 | 14116 | 0.01 | Why? |
| China | 1 | 2021 | 50654 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.01 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |